---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-023988"
form_type: "8-K"
ticker: "HROW"
cik: "0001360214"
company_name: "HARROW, INC."
filed_at: "2025-11-18T23:59:59+00:00"
generated_at: "2026-05-16T18:44:06.032462+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.45
calibrated_materiality_score: 0.45
confidence: "high"
source: SEC EDGAR
---

# Harrow completes Melt acquisition for ~$4.3M cash; outlines MELT-300 NDA timeline

## Summary
- Paid ~$4.3M cash at closing for remaining Melt equity; contingent milestone payments unchanged.
- Acquires Melt pipeline: MELT-300 (Phase 3, SPA), MELT-210, MELT-400; expands into procedural sedation.
- Next steps for MELT-300: PK studies, NDA submission H1 2027, potential approval H1 2028, launch H2 2028.
- MELT-300 is a sublingual midazolam/ketamine formulation; could be first FDA-approved non-opioid non-IV sedation.
- Integration of Melt into Harrow's operations; leveraging MKO Melt network for commercial readiness.

## SEC filing metadata
- accession: 0001493152-25-023988
- form_type: 8-K
- ticker: HROW
- cik: 0001360214
- company_name: HARROW, INC.
- filed_at: 2025-11-18T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.45
- calibrated_materiality_score: 0.45
- confidence: high
- sec_items: 2.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1360214/000149315225023988/0001493152-25-023988-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1360214/000149315225023988/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-023988
- JSON: https://secwatch.observer/filing/0001493152-25-023988.json
- Plain text: https://secwatch.observer/filing/0001493152-25-023988.txt

## Source-grounded claims
- claim_id: 70fbf7b3071d1406519b9c763035e86bee1c2870
  claim: HARROW, INC. completed an acquisition involving Melt Pharmaceuticals, Inc. for approximately $4.3 million in cash (closed 2025-11-17).
  evidence_excerpt: in the Company’s Current Report on Form 8-K filed on September 26, 2025, which description is incorporated herein by reference. At closing, the Company paid approximately $4.3 million in cash as initial consideration for the remaining equity interests of Melt. The contingent regulatory and commercial milestone payments described in the Company’s September 26,
  evidence_url: https://www.sec.gov/Archives/edgar/data/1360214/000149315225023988/0001493152-25-023988-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.